Research
Hormonal
Obesity is associated with an increased risk of triple-negative breast cancer (TNBC) in premenopausal women, whereas this association is null or inverse in postmenopausal women.
For premenopausal women, obesity specifically increases the risk of the more aggressive triple-negative breast cancer subtype. Weight management is particularly crucial in this demographic.
GoodQualifiesMEDIUM confidence
In contrast to ER-positive breast cancers, obesity is associated with a higher risk of premenopausal ER-negative breast cancer and TNBC in most studies... the risk of ER-negative breast cancer and TNBC is minimally or inversely associated with obesity after menopause.
Why this rating
Supported by multiple meta-analyses and large cohort studies.
Source
Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention
Manuel Picon‐Ruiz et al. · CA A Cancer Journal for Clinicians · 2017
DOI 10.3322/caac.21405
narrative_reviewCited 951×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity increases the risk of postmenopausal estrogen receptor-positive (ER+) breast cancer and is associated with worse disease outcomes and higher mortality across all breast cancer subtypes.Strong
- Obesity promotes aggressive breast cancer behavior (growth, invasion, metastasis) through a mechanism involving hypoxia-induced inflammation, increased aromatase expression, and stimulation of cancer stem cells.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →